John Coon
10Patents
3h-index
9Co-inventors
53Inventor score
Filing activity: May 19, 1995 → Feb 9, 2016
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5591715A | Methods and compositions for reducing multidrug resistance | Human Necessities | 18 | Expired |
| US5776891A | Compositions for reducing multidrug resistance | Human Necessities | 10 | Expired |
| US5681812A | Methods and compositions for reducing multidrug resistance | Human Necessities | 4 | Expired |
| US9291625B2 | Diagnostic methods for determining prognosis of non-small cell lung cancer | Physics | 1 | Active |
| US8951725B2 | Diagnostic methods for determining prognosis of non-small cell lung cancer | Chemistry; Metallurgy | 1 | Active |
| US9994909B2 | Diagnostic methods for determining prognosis of non-small cell lung cancer | Chemistry; Metallurgy | 0 | Active |
| US8105768B2 | Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number | Chemistry; Metallurgy | 0 | Expired |
| US9297045B2 | Diagnostic methods for determining prognosis of non-small cell lung cancer | Chemistry; Metallurgy | 0 | Active |
| US10047403B2 | Diagnostic methods for determining prognosis of non-small cell lung cancer | Physics | 0 | Active |
| US8785131B2 | Prognostic test for early stage non small cell lung cancer (NSCLC) | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.